News | Heart Valve Technology | September 26, 2022

Edwards Launches Sapien 3 Ultra Resilia Valve Following FDA Approval

Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.

September 26, 2022 — Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve. The launch follows recent U.S. Food and Drug Administration(FDA) approval. 

RESILIA tissue is a bovine pericardial tissue treated with advanced anti-calcification technology and serves as the platform for Edwards' new class of valves, including the next generation SAPIEN X4 valve, which is currently undergoing clinical trials. RESILIA tissue delivers important advances to the SAPIEN 3 Ultra platform including enhanced calcium blocking properties and dry tissue packaging conditions that facilitate ease of use. RESILIA tissue has demonstrated freedom from structural valve deterioration at 5 years and provides the potential to extend the durability of the SAPIEN 3 Ultra RESILIA valve. It is used in the world's leading surgical aortic valve, the Edwards INSPIRIS RESILIA valve. 

"The SAPIEN 3 Ultra RESILIA valve builds on Edwards' 40 years of leadership in tissue technology by combining advancements in tissue science with the industry leading SAPIEN 3 Ultra valve to offer the only dry storage transcatheter heart valve on the U.S. market today," said Larry Wood, corporate vice president, transcatheter aortic valve replacement. "The RESILIA tissue's anti-calcification technology addresses one of the primary causes of reintervention following heart valve replacement. The SAPIEN 3 Ultra RESILIA valve is a prime example of Edwards' continued focus on innovating to meet the current and future needs of patients to help them live longer, healthier and more productive lives." 

The SAPIEN 3 Ultra RESILIA valve will be available in the U.S. in limited release in the fourth quarter of 2022. The commercial opportunity related to this approval is factored into 2022 financial expectations. 

For more information: www.edwards.com 

Find more TCT22 coverage here 


Related Content

News | Heart Valve Technology

February 28, 2023 — On Feb. 27, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to ...

Home February 28, 2023
Home
News | Heart Valve Technology

January 23, 2023 — Leakage of the mitral valve due to degenerative prolapse is a common condition known as primary ...

Home January 23, 2023
Home
News | Heart Valve Technology

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has given the approval to market to The Edwards ...

Home January 02, 2023
Home
News | Heart Valve Technology

December 29, 2022 — The Smidt Heart Institute at Cedars-Sinai was named a Mitral Valve Repair Reference Center, a ...

Home December 29, 2022
Home
News | Heart Valve Technology

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping ...

Home December 14, 2022
Home
News | Heart Valve Technology

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve ...

Home November 22, 2022
Home
News | Heart Valve Technology

October 18, 2022 — Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive ...

Home October 18, 2022
Home
News | Heart Valve Technology

October 18, 2022 — The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its ...

Home October 18, 2022
Home
News | Heart Valve Technology

September 15, 2022 — Cardiac Implants LLC has announced the successful initial deployment of its Annuloplasty ring with ...

Home September 15, 2022
Home
News | Heart Valve Technology

September 9, 2022 — The U.S. Food and Drug Administration (FDA) is alerting healthcare providers about potential clip ...

Home September 09, 2022
Home
Subscribe Now